# A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

> **NCT06412666** · PHASE2,PHASE3 · RECRUITING · sponsor: **Cytokinetics** · enrollment: 55 (estimated)

## Conditions studied

- Pediatric
- Symptomatic Obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Aficamten
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06412666
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06412666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06412666, "A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06412666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*